Table 3.
Summary of interactions
| Multiplicative model | ||||
|---|---|---|---|---|
| Measure of interaction | Additive model | |||
| Measure of interaction δ | P-value | Measure of interaction δ | P-value | |
| Known interaction | ||||
| Simvastatin-ciclosporin and MYP | 1.48 | 0.089 | 0.014 | 0.0002 |
| Methotrexate-diclofenac and BMD | 1.79 | 0.015 | 0.009 | 0.001 |
| Ketoconazole-terfenadine and TdP | 1.71 | 0.27 | 0.011 | 0.038 |
| Cisapride-erythromycin and TdP | 0.32 | 0.0001 | 0.013 | 0.014 |
| No known interaction | ||||
| Methotrexate-rofecoxib and BMD | 0.34 | 0.14 | −0.004 | 0.0001 |
| Fluvastatin-ciclosporin and MYP | 0.26 | 0.19 | −0.002 | 0.83 |
| Cisapride-azithromycin and TdP | 0.11 | 0.002 | −0.0047 | 0.01 |
| Fexofenadine-ketoconazole and TdP | 0 | * | −0.002 | 0.0001 |
P value not estimated as one cell contains 0. BMD bone marrow depression; MYP myopathy; TdP Torsades de Pointes.